In the IMpower-010 trial, patients with resected stage IB-IIIA PD-L1 ≥ 1% NSCLC (TNM7), treated with adjuvant PBC, were randomized to 1-year atezolizumab (PD-L1 inhibitor) versus best-supportive care. Here, CD274 is linked to primary biliary cholangitis.